BRÈVE

sur MindBio Therapeutics (isin : CA60256C1086)

MindBio Therapeutics Appoints Haywood Securities for Strategic Investment Advisory

VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), a leading biopharmaceutical company in psychiatric medicine development, has announced the appointment of Haywood Securities Inc. as its strategic advisor. Haywood will assist MindBio in securing potential strategic investments and transactions.

The agreement includes fees paid in Warrants, with up to 7,500,000 Warrants issued for a commitment of six months. Customary success fees apply upon the successful completion of a transaction.

MindBio has multiple Phase 2B clinical trials underway, which include regulatory approval for take-home use of their lead candidate, MB22001. The drug has shown promising results in depression trials.

MindBio's focus is on microdosing psychedelic medicines as an effective and affordable treatment for mental health conditions. Current trials include studies for depression and cancer, with a recent addition for PMS/PMDD.

Justin Hanka, CEO of MindBio, expressed enthusiasm for the partnership with Haywood to lead their strategic investment initiatives.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de MindBio Therapeutics